# Docetaxel in Treating Children With Recurrent Solid Tumors

> **NCT00002825** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Neuroblastoma
- Sarcoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00002825
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002825, "Docetaxel in Treating Children With Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00002825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*